Dr. Patricia Gutiérrez-Ontalvilla
PhD Cum Laude · Specialist in Plastic, Aesthetic, and Reconstructive Surgery · National Secretary for Spain ISAPS · President Nixarian Foundation | dragutierrez.com
How many PRP sessions are needed for vulvar lichen sclerosus?
We analyze the real evidence, the most common myths, and the alternatives with the strongest scientific backing.
Direct answer: There is no scientifically validated frequency protocol for vulvar PRP in lichen sclerosus. The only randomized, placebo-controlled clinical trial published to date—Goldstein et al., Journal of the American Academy of Dermatology, 2019—concluded that isolated PRP does not adequately treat vulvar lichen sclerosus. The strongest available evidence today points to treatments based on stem cells obtained from the patient’s own fat: nanofat and stromal vascular fraction (SVF), such as the Liquenia Protocol, which has achieved the highest level of scientific evidence in this field to date.
If you have been diagnosed with vulvar lichen sclerosus and are looking for alternatives to topical corticosteroids, you have probably heard of PRP. Many clinics present it as a regenerative, “natural” treatment with almost no risks. The scientific reality, however, is much more nuanced. And knowing it before making a decision matters: in terms of time, money, and health.
This article specifically analyzes PRP used in isolation—without combining it with nanofat or cells obtained from adipose tissue—which is how it is usually offered in gynecology and dermatology clinics. We will see what science says about its efficacy, what myths are most frequently circulated, for which patients it is not indicated, and which options currently have real and documented clinical support.
Only double-blind placebo-controlled trial in VLS (Goldstein, JAAD 2019)
Between PRP and saline in histological biopsy
LIQUENIA nanofat + SVF clinical trial in VLS (EudraCT)
Liquenia-SVF Protocol with clinical and histological improvement at 12 months
What is PRP and how does it work in lichen sclerosus?
PRP (platelet-rich plasma) is obtained by taking a small sample of your own blood and centrifuging it to concentrate the platelets. These platelets contain molecules called growth factors which, in theory, could stimulate tissue repair and modulate inflammation. In the context of vulvar lichen sclerosus, it is injected directly into the affected area, at multiple points in the vulvar mucosa and dermis.
The hypothesis has a certain biological logic. The problem is that in real clinical practice, it has not yielded the results that this logic promised. And the fact that a substance comes from your own blood does not guarantee absolute safety or efficacy.
Myth #1: “PRP contains stem cells”
Scientific clarification: PRP is plasma with platelets. It does not contain stem cells. This statement, which frequently appears in the communications of some clinics, is scientifically incorrect. Therapies that do contain regenerative cellular components are nanofat and stromal vascular fraction (SVF), obtained from your own adipose tissue (fat).
The confusion is understandable: both PRP and nanofat are autologous—from your own body—and are applied in a similar way. But they are completely different. Mesenchymal stem cells with real regenerative capacity are found in the stromal fraction of adipose tissue, not in blood plasma. PRP releases platelet-derived growth factors; nanofat and SVF release cellular signals with a much deeper mechanism of action on chronic inflammation and the fibrosis characteristic of lichen sclerosus.
Myth #2: “PRP has solid scientific evidence for lichen sclerosus”
This is the most important point of the article, and the one most rarely communicated clearly to patients. In 2019, the Journal of the American Academy of Dermatology published the only randomized, double-blind, placebo-controlled clinical trial conducted to date to evaluate isolated PRP in vulvar lichen sclerosus. It was authored by Goldstein and his team. The study design is the most rigorous possible: neither patients nor doctors knew who received PRP and who received saline.
“Until well-designed controlled studies show positive results, the negative results of this study suggest that autologous PRP does not adequately treat vulvar lichen sclerosus.”
Goldstein AT et al., J Am Acad Dermatol. 2019;80(6):1788-9. Double-blind RCT, n=29 patients.
In that study, 20 patients received PRP and 10 received saline injections. When analyzing biopsies before and after treatment, the reduction in tissue inflammation was statistically identical in both groups. The subjective improvement reported by some patients was also not significantly different between those who received PRP and those who received salt water.
The clinical practice guideline of the International Society of Aesthetic Plastic Surgery (ISAPS, 2025)—published in Aesthetic Plastic Surgery with Dr. Gutiérrez-Ontalvilla as first author—explicitly states this fact: it classifies the evidence level of isolated PRP in vulvar lichen sclerosus as 2b for case series with positive results, but assigns level 1b—the highest available—to the only existing controlled trial, which concludes negatively.
It is true that there are case series with positive results. But without a placebo control group, it is impossible to know whether that improvement was caused by PRP or simply by the passage of time, local anesthesia, patient expectation, or the natural variability of the disease.
Myth #3: “PRP is suitable for any patient with lichen sclerosus”
In addition to its debated efficacy, there are clinical situations where PRP should not be performed or requires special caution. This aspect rarely appears in the materials of clinics that offer it.
| Type | Clinical situation |
|---|---|
| Absolute contraindication | Active cancer (risk of tumor dissemination) |
| Absolute contraindication | Severe coagulation disorders (hemophilia, severe coagulopathies) |
| Absolute contraindication | Severe thrombocytopenia or active infection in the area to be treated |
| Important precaution | Aspirin, clopidogrel (Plavix) — reduce growth factor release |
| Important precaution | Oral anticoagulants: Sintrom, warfarin, rivaroxaban, apixaban, dabigatran |
| Important precaution | NSAIDs (ibuprofen, naproxen) — discontinue 7-10 days prior if possible |
| Important precaution | Pregnancy, lactation, severe chronic liver disease, poorly controlled diabetes |
Relevant clinical data: The patient profile taking aspirin, clopidogrel, or oral anticoagulants is very common in women over 50—precisely the age group most affected by vulvar lichen sclerosus. In these cases, PRP is not only less effective: it may be directly contraindicated or require the suspension of essential cardiac medication. These indications come from the formal GRIIP consensus (Eymard et al., Knee Surg Sports Traumatol Arthrosc., 2025).
Myth #4: “There is a validated protocol for how many sessions to perform”
The most common cycle—2 or 3 initial sessions separated by several weeks, followed by maintenance every 6 to 12 months—is an empirical proposal, not a recommendation supported by trials with positive results. There is no scientifically validated frequency protocol for PRP in vulvar lichen sclerosus, precisely because the treatment itself has not demonstrated superior efficacy to placebo.
This means that the question “how often should PRP be repeated?” currently has no answer that science can support. And investing in repeated cycles of a treatment whose efficacy is not proven is a decision that deserves to be considered with complete information.
Myth #5: “It is a minimally invasive and painless procedure”
PRP is usually presented as a procedure performed in the clinic with topical anesthetic cream. In practice, it involves injecting between 5 and 10 ml of plasma into multiple points of the vulvar mucosa and dermis—an area that is already inflamed, sensitive, and usually painful in patients with active lichen sclerosus.
Patients consistently describe that local anesthetic cream is insufficient to control pain during the procedure, and that the experience is significantly more painful than what they were led to expect during the informational consultation. This is a fact that rarely appears in the promotional materials for this treatment.
What changes when real stem cells are used: nanofat and SVF
The fat in your own body contains something that blood plasma does not: adipose-derived mesenchymal stem cells (known as ADSCs). These cells have a regenerative, anti-inflammatory, and immunomodulatory capacity that available studies have objectively documented, even in biopsy.
There are two main ways to obtain and apply them in vulvar lichen sclerosus:
- Nanofat: the patient’s own fat emulsified until very fluid, rich in stromal fraction and regenerative mediators. It improves the texture, vascularization, and elasticity of damaged vulvar tissue. It was the subject of the LIQUENIA clinical trial, the first with level 1 evidence in this field (EudraCT Number 2016-003952-63; ClinicalTrials.gov: NCT03961126), conducted at the La Fe Hospital Research Institute in Valencia.
- SVF (Stromal Vascular Fraction): a concentrated mixture of regenerative cells mechanically obtained from one’s own fat, without enzymes. It contains mesenchymal stem cells, pericytes, endothelial progenitors, and reparative macrophages—components that act simultaneously on inflammation, fibrosis, and angiogenesis (formation of new blood vessels).
When nanofat is combined with SVF, the regenerative effect is demonstrably greater. Available studies show improvements in clinical and histological parameters (tissue biopsy): less fibrosis, less inflammation, more functional vessels.
Liquenia-SVF Protocol — published study data: In a prospective study of 18 women with moderate-to-severe vulvar lichen sclerosus refractory to corticosteroids, a single session of nanofat + SVF produced significant improvement in pruritus, burning, pain, and clinical signs at 12 months. Biopsies showed reduced fibrosis (collagen hyalinization), fewer CD3+ inflammatory lymphocytes, and increased microvascular density. There were no serious adverse events. Results published in Aesthetic Surgery Journal (Oxford, 2025, DOI: 10.1093/asj/sjaf148) and included in the ISAPS 2025 clinical practice guideline (DOI: 10.1007/s00266-025-05459-7).
Comparison of Regenerative Treatments for Vulvar Lichen Sclerosus
| Treatment | Contains stem cells? | Evidence level | Main conclusion |
|---|---|---|---|
| Topical corticosteroid (clobetasol 0.05%) | — | 1a (first-line) | Reduces inflammation and prevents progression. Reference treatment. |
| Isolated PRP | ❌ No | 1b (negative) · 2b (case series) | The only double-blind RCT concludes that it does not adequately treat VLS. |
| Nanofat + SVF (Liquenia) | ✅ Yes (ADSCs, pericytes, endothelial progenitors) | Level 1 in nanofat clinical trial; prospective SVF study published in ASJ 2025 | Documented clinical and histological improvement in corticosteroid-refractory patients. |
So, how often should vulvar PRP be repeated for lichen sclerosus?
The honest answer, based on available evidence, is that there is no validated frequency, because isolated PRP has not been shown to be more effective than placebo in the only rigorous study conducted. The protocols in circulation—2 or 3 initial sessions plus maintenance—are empirical proposals without the backing of controlled trials with positive results.
Perhaps the most useful question is not how many PRP sessions you need, but whether PRP is truly the right treatment for your case. Before starting any cycle, I recommend that you check if you are taking any of the medications mentioned in this article, ask for information about the real level of evidence for what is being proposed to you, and evaluate whether there are options with greater scientific support adapted to your specific clinical situation.
Frequently Asked Questions
The highest level of evidence—the only randomized, double-blind, placebo-controlled clinical trial—concludes that isolated PRP does not adequately treat vulvar lichen sclerosus (Goldstein et al., JAAD, 2019, n=29). There are case series with positive results, but they are of a lower level of evidence and do not rule out a placebo effect.
No. PRP is platelet-rich plasma, obtained from blood. It does not contain stem cells. Therapies with real regenerative stem cells are obtained from adipose tissue (own fat): these are nanofat and stromal vascular fraction (SVF).
There is no scientifically validated frequency protocol. Cycles of 2-3 sessions plus maintenance every 6-12 months are empirical proposals without the backing of controlled trials with positive results in vulvar lichen sclerosus.
PRP is contraindicated in active cancer, severe coagulation disorders, severe thrombocytopenia, and active infection in the area to be treated. It requires special caution with aspirin, clopidogrel, oral anticoagulants (Sintrom, warfarin, rivaroxaban, apixaban, dabigatran), and NSAIDs like ibuprofen. This medication profile is very common in women over 50, the group most affected by lichen sclerosus. Source: Eymard et al., GRIIP consensus, 2025.
No. Vulvar lichen sclerosus is a chronic condition with no known cure according to current clinical consensus (ISSVD 2022). No available treatment, including PRP, eradicates the disease. The goal is to control symptoms, slow progression, and improve quality of life sustainably.
For patients who do not respond sufficiently to topical corticosteroids, current evidence points to nanofat and stromal vascular fraction (SVF) obtained from one’s own fat. The Liquenia-SVF protocol has shown clinical and histological improvement with a single session in women with moderate-to-severe refractory lichen sclerosus (Aesthetic Surgery Journal, Oxford, 2025, DOI: 10.1093/asj/sjaf148).
The indicative cost per session usually ranges between 500 and 700 euros. A complete cycle of 2-3 sessions can exceed 2,000 euros, without any documented guarantee of efficacy in controlled trials for vulvar lichen sclerosus.
Reviewed and written by Dr. Patricia Gutiérrez-Ontalvilla, PhD cum laude (University of Valencia), Specialist in Plastic, Aesthetic, and Reconstructive Surgery, National Secretary for Spain of the International Society of Aesthetic Plastic Surgery (ISAPS), President of the Nixarian Foundation and first author of the guideline State of the Art for Regenerative Management of Vulvar Lichen Sclerosus (Aesthetic Plastic Surgery, ISAPS 2025, DOI: 10.1007/s00266-025-05459-7). This article is based on scientific evidence published in indexed journals and does not replace individualized medical consultation.
Do you have questions about which treatment is most suitable for your case?
At Liquenia, we perform online and in-person medical assessments for patients with vulvar lichen sclerosus. We explain what the evidence says about each option, which one fits your clinical situation—including your current medication—and what you can realistically expect from each treatment.
Scientific References
- Goldstein AT, Mitchell L, Govind V, Heller D. A randomized double-blind placebo-controlled trial of autologous platelet-rich plasma intradermal injections for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol. 2019;80(6):1788–9. DOI: 10.1016/j.jaad.2018.12.060
- Gutierrez-Ontalvilla P, Benito-Ruiz J, Cervantes A. State of the art for regenerative management of vulvar lichen sclerosus. Aesth Plast Surg. 2025. DOI: 10.1007/s00266-025-05459-7
- Gutierrez-Ontalvilla P et al. [Liquenia-SVF Study]. Aesthetic Surgery Journal. Oxford, 2025. DOI: 10.1093/asj/sjaf148
- Eymard F et al. Indications and contraindications to PRP injections: a 2025 formal consensus from the GRIIP. Knee Surg Sports Traumatol Arthrosc. 2025.
